Back to journals
Academic Journal

JAMA

3 Papers Indexed in Blossom

Data updated

Research Footprint

JAMA has 3 tracked papers indexed in Blossom (2021–2025) from 19 authors, most often covering Psilocybin, LSD and Placebo, across Anxiety Disorders, Depressive Disorders and Older Adults.

Published Papers

Paywallindividual

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial

In a multicentre phase 2b randomised placebo‑controlled trial of 198 adults with moderate to severe GAD, a single dose of MM120 (lysergide D‑tartrate) produced a dose‑dependent reduction in HAM‑A scores at 4 weeks, with 100 µg and 200 µg showing significant improvements versus placebo (least‑squares mean differences −5.0 and −6.0 points, respectively). Adverse events were dose‑related—most commonly visual perceptual changes and nausea—supporting the efficacy and informing dose selection for phase 3 trials.

Published
Journal
JAMA
Authors
Robison, R., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Karas, S. M., Karlin, D. R., Solomon, T. M., Wernli, M. H., Fava, M. F., Jemisen, J.
Paywallindividual

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

In a randomised, double‑blind phase 2 trial of 104 adults with moderate-to-severe major depressive disorder, a single 25 mg dose of psilocybin with psychological support produced significantly greater and sustained reductions in depressive symptoms (MADRS mean difference −12.3 at day 43) and functional disability versus niacin placebo. No serious treatment‑emergent adverse events were reported, although psilocybin was associated with higher overall and severe adverse event rates.

Published
Journal
JAMA
Authors
Raison, C. L., Sanacora, G., Woolley, J. D., Ross, S., Griffiths, R. R.
Paywallindividual

Two Models of Legalization of Psychedelic Substances: Reasons for Concern

This opinion paper (2021) raises concerns over the two concurrent models of legalizing the possession, personal use, and noncommercial sharing of psychedelics in California and clinical use in Oregon. In light of cautionary precedents involving the commercialisation of ketamine and cannabis, their chief concern is that non-evidence-based marketing strategies founded on one-sided enthusiasm for the benefits of psychedelics may supplant evidence-based practices, thereby putting vulnerable populations at risk of their potential side effects that have not been studied outside of the clinical population.

Published
Journal
JAMA
Authors
Smith, W. R., Appelbaum, P. S.

Quick Facts

Papers Indexed
3
h-Index
794
Open Access
No
Publisher
American Medical Association
Country
United States
Website
Visit